Connect with us

Hi, what are you looking for?


Scotland First in World to Use New Diabetes Test

The blood test for people with Type 1 diabetes may allow some patients to stop taking insulin altogether.

Scotland First in World to Use New Diabetes Test

Scotland will become the first country to offer the C-peptide blood test to all patients who have had a Type 1 diagnosis for at least three years.

The test shows how much insulin a patient’s body is producing itself.

A pilot by NHS Lothian allowed some people who had been taking insulin to stop or reduce the treatment. The test will be available from 1 November.

C-peptide testing, which has been used as part of diagnosis for some patients for many years, can help distinguish whether a patient has Type 1 or Type 2 diabetes.


C-peptide is made in the body at the same time as insulin. By testing levels of C-peptide, doctors can work out how much insulin a diabetes patient is making themselves.

If C-peptide is present in significant amounts, it might indicate that the person does not have Type 1 diabetes at all, and consequently may not need daily insulin injections.

This is what was discovered during a two-year pilot study led by diabetes and endocrinology consultant Prof Mark Strachan.

Professor Mark Strachan
During a pilot study, Prof Mark Strachan was able to stop some patients taking insulin


Prof Strachan said: “C-peptide helps diabetes specialists make a more accurate diagnosis of the cause of diabetes, and that means we can get people on the most appropriate treatment.

“In some instances, C-peptide testing allowed people to stop very long-standing insulin therapy. This can be life-transforming.

“If anyone has any concerns regarding their diabetes or wishes to know more about the new blood test, they should contact their diabetes clinical team who are best placed to provide specific advice and support based on their individual circumstances.”

‘Significant positive impact’

There are about 315,000 people living with diabetes in Scotland and the new programme will be offered to people who have been diagnosed with Type 1 diabetes for at least three years.

The tests will be offered at hospital diabetes centres.

Public Health Minister Maree Todd said that tackling diabetes was a priority for the Scottish government and that she wanted everyone living with diabetes to access safe, effective healthcare, treatment and support.

She said: “Type 1 diabetes is a significant health challenge right across the world.

“I am proud that Scotland will be the first country to introduce this blood test which has the potential to have a significant positive impact on the lives of those people living with diabetes.”

Seen on BBC (Health): Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News


PocDoc, the digital health platform and personal diagnostics provider, has launched what it says is a world-first smartphone-based test for cardiovascular disease.


Focused on connecting startups in the Medtech industry with potential investors, this can't miss event features the globe's most promising companies


The technology could greatly aid spinal surgeons in planning surgical interventions in advance.   


Emerging HealthTech company, Stasis Labs, Inc. intends to bridge the gap between clinicians and their patients with an all-in-one FDA-cleared hardware and software solution,...

You May Also Like


Today & Tomorrow: Digital Solutions in HealthTech Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare...


In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...


Software as a Medical Device (SaMD) is driving innovation in the HealthTech space and is more popular than ever — completely upending the way...


The sky’s the limit for HealthTech PR and looking past traditional strategies to nontraditional avenues for engagement will allow agencies to stand out.